KEGG   PATHWAY: tup05220
Entry
tup05220                    Pathway                                
Name
Chronic myeloid leukemia - Tupaia chinensis (Chinese tree shrew)
Description
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.
Class
Human Diseases; Cancer: specific types
Pathway map
tup05220  Chronic myeloid leukemia
tup05220

Organism
Tupaia chinensis (Chinese tree shrew) [GN:tup]
Gene
102489957  BCR; BCR, RhoGEF and GTPase activating protein [KO:K08878] [EC:2.7.11.1]
102470554  ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase [KO:K06619] [EC:2.7.10.2]
102482865  CRKL; CRK like proto-oncogene, adaptor protein [KO:K04438]
102486599  CRK; CRK proto-oncogene, adaptor protein [KO:K04438]
102469580  CBL; Cbl proto-oncogene [KO:K04707] [EC:2.3.2.27]
102500530  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
102502163  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
102483329  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
106736453  phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform-like [KO:K00922] [EC:2.7.1.153]
102469401  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
102484444  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
102484500  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
102472172  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
102492771  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
102474297  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
102498069  BAD; BCL2 associated agonist of cell death [KO:K02158]
102486626  BCL2L1; BCL2 like 1 [KO:K04570]
102501308  CHUK; conserved helix-loop-helix ubiquitous kinase [KO:K04467] [EC:2.7.11.10]
102467954  IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta [KO:K07209] [EC:2.7.11.10]
102476758  IKBKG; inhibitor of nuclear factor kappa B kinase subunit gamma [KO:K07210]
102494635  NFKBIA; NFKB inhibitor alpha [KO:K04734]
102487413  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
102490451  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
102473924  MDM2; MDM2 proto-oncogene [KO:K06643] [EC:2.3.2.27]
102503238  TP53; tumor protein p53 [KO:K04451]
102501235  CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624]
102493080  GRB2; growth factor receptor bound protein 2 [KO:K04364]
102490988  GAB2; GRB2 associated binding protein 2 [KO:K08091]
102485136  PTPN11; protein tyrosine phosphatase, non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
102498455  tyrosine-protein phosphatase non-receptor type 11-like [KO:K07293] [EC:3.1.3.48]
102494629  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
102477222  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
102493230  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
102500069  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
102496534  NRAS; neuroblastoma RAS viral oncogene homolog [KO:K07828]
102497488  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
102493239  ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
102477389  BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
102476496  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
102483700  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
102496453  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
102483057  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
102481002  SHC1; SHC adaptor protein 1 [KO:K06279]
102481863  SHC2; SHC adaptor protein 2 [KO:K17447]
102472295  SHC3; SHC adaptor protein 3 [KO:K17448]
102479734  SHC4; SHC adaptor protein 4 [KO:K17449]
102501999  MYC; v-myc avian myelocytomatosis viral oncogene homolog [KO:K04377]
102481444  STAT5A; signal transducer and activator of transcription 5A [KO:K11223]
102492323  STAT5B; signal transducer and activator of transcription 5B [KO:K11224]
102490159  CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625]
102490651  CCND1; cyclin D1 [KO:K04503]
102493291  CDK4; cyclin dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
102488432  CDK6; cyclin dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
102499507  RB1; RB transcriptional corepressor 1 [KO:K06618]
102484832  E2F1; E2F transcription factor 1 [KO:K17454]
102479669  E2F2; E2F transcription factor 2 [KO:K09389]
102499416  E2F3; E2F transcription factor 3 [KO:K06620]
102496861  GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402]
102476523  GADD45B; growth arrest and DNA damage inducible beta [KO:K04402]
102502813  GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402]
102471776  BAX; BCL2 associated X, apoptosis regulator [KO:K02159]
102476690  BAK1; BCL2 antagonist/killer 1 [KO:K14021]
102472614  DDB2; damage specific DNA binding protein 2 [KO:K10140]
102479454  POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7]
102488524  TGFB1; transforming growth factor beta 1 [KO:K13375]
102500482  TGFB2; transforming growth factor beta 2 [KO:K13376]
102497029  TGFB3; transforming growth factor beta 3 [KO:K13377]
102476700  TGFBR1; transforming growth factor beta receptor 1 [KO:K04674] [EC:2.7.11.30]
102486518  TGFBR2; transforming growth factor beta receptor 2 [KO:K04388] [EC:2.7.11.30]
102473158  SMAD3; SMAD family member 3 [KO:K23605]
102494008  SMAD4; SMAD family member 4 [KO:K04501]
102488385  MECOM; MDS1 and EVI1 complex locus [KO:K04462] [EC:2.1.1.367]
102496134  RUNX1; runt-related transcription factor 1 [KO:K08367]
102499964  CTBP2; C-terminal binding protein 2 [KO:K04496] [EC:1.1.1.428]
102494077  CTBP1; C-terminal binding protein 1 [KO:K04496] [EC:1.1.1.428]
102468100  HDAC1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98]
102503291  HDAC2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98]
Compound
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Ren R.
  Title
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
  Journal
Nat Rev Cancer 5:172-83 (2005)
DOI:10.1038/nrc1567
Reference
  Authors
Deininger MW, Goldman JM, Melo JV.
  Title
The molecular biology of chronic myeloid leukemia.
  Journal
Blood 96:3343-56 (2000)
Reference
  Authors
Calabretta B, Perrotti D.
  Title
The biology of CML blast crisis.
  Journal
Blood 103:4010-22 (2004)
DOI:10.1182/blood-2003-12-4111
Reference
  Authors
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
  Title
The biology of chronic myeloid leukemia.
  Journal
N Engl J Med 341:164-72 (1999)
DOI:10.1056/NEJM199907153410306
Reference
  Authors
Mitani K.
  Title
Molecular mechanisms of leukemogenesis by AML1/EVI-1.
  Journal
Oncogene 23:4263-9 (2004)
DOI:10.1038/sj.onc.1207777
Reference
  Authors
Dong M, Blobe GC.
  Title
Role of transforming growth factor-beta in hematologic malignancies.
  Journal
Blood 107:4589-96 (2006)
DOI:10.1182/blood-2005-10-4169
Reference
PMID:9834202
  Authors
Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
  Title
The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
  Journal
Blood 92:4003-12 (1998)
Reference
  Authors
Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
  Title
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
  Journal
Haematologica 88:622-30 (2003)
Reference
  Authors
Baldwin AS.
  Title
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
  Journal
J Clin Invest 107:241-6 (2001)
DOI:10.1172/JCI11991
Reference
  Authors
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.
  Title
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
  Journal
Nat Med 8:1145-52 (2002)
DOI:10.1038/nm759
Reference
  Authors
Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V
  Title
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
  Journal
Nat Chem Biol 8:285-93 (2012)
DOI:10.1038/nchembio.775
Related
pathway
tup04010  MAPK signaling pathway
tup04110  Cell cycle
tup04115  p53 signaling pathway
tup04151  PI3K-Akt signaling pathway
tup04210  Apoptosis
tup04350  TGF-beta signaling pathway
tup04640  Hematopoietic cell lineage
KO pathway
ko05220   
LinkDB

DBGET integrated database retrieval system